---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000283"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:37:53.346120+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization

## Summary
- Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.
- GAAP loss from continuing ops $33.5M ($1.93/sh); non-GAAP operating loss $4.4M.
- Recorded $41.9M intangible impairment (DetermaCNI $35.1M, DetermaIO $6.8M) offset by $13.7M contingent consideration gain.
- Cash $10.3M at year-end; raised $29.1M in Feb 2025 offering; Bio-Rad holds ~9.66% stake.
- Targeting FDA submission for kitted transplant assay GraftAssureDx by end 2025; authorization expected 2026.

## SEC filing metadata
- accession: 0001641172-25-000283
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/0001641172-25-000283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000164117225000283/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000283
- JSON: https://secwatch.observer/filing/0001641172-25-000283.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.